ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Anticoagulation Use for Portal Vein Thrombosis in University of Wisconsin Liver Transplant Patients.

M. Falls,1 A. Said,2 L. Fernandez,2 D. Foley,2 K. Frith,1 D. Hager,2 H. Hoy,1 G. Leverson,2 J. Mezrich,2 T. Prickette,2 M. Wakefield,2 A. D'Alessandro.2

1School of Nursing, University of Alabama, Huntsville, AL
2Transplant Surgery, University of Wisconsin, Madison, WI.

Meeting: 2016 American Transplant Congress

Abstract number: C227

Keywords: Liver transplantation, Outcome, Portal veins, Prophylaxis

Session Information

Session Name: Poster Session C: Liver Transplantation Complications and Other Considerations

Session Type: Poster Session

Date: Monday, June 13, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Background: The prevalence of Portal Vein Thrombosis (PVT) in cirrhotic liver transplant patients increases the risk of morbidity and mortality post-liver transplantation. Current research suggests that PVT should be managed with anticoagulation in those with cirrhosis that are waiting for liver transplant. Anticoagulation therapy and management is not uniformly practiced in pre-liver transplant patients with cirrhosis and PVT, nor are there established clinical guidelines.

The purpose of this study was to compare the outcomes in mortality following liver transplant in patients from the University of Wisconsin who had PVT prior to transplantation and were, or were not treated with anticoagulation.

Methods: This was a single-institution, retrospective review from a prospectively collected database to evaluate the utility of anticoagulation therapy in patients with PVT that underwent liver transplantation between January 1, 2006 and June 30, 2014. The primary outcome of interest was patient mortality. Patients were excluded as a result of additional diagnoses including atrial fibrillation, cerebral vascular accident, pulmonary emboli and deep vein thrombosis.

Results: From a total of 755 liver transplants performed between January 1, 2006 and June 30, 2014, 56 patients with PVT were evaluated in this study(Table 1). There was no statistically significant difference in mortality between the 4 groups in table 1 (p = 0.67).

Conclusion: This study suggests the use of anticoagulation and thrombectomy at liver transplant may improve the mortality outcomes in this population (Table 1). The results are not statistically significant, likely due to the small sample size.

A multi-center study of the same design would be of benefit to improve the power of the data and better evaluate the use of anticoagulation therapy in the liver transplant patient with PVT. Review of this data in 2 years would allow us to continue to further evaluate morbidity and mortality in this patient cohort.

Variable

N Percent 5 year Mortality (p=0.67)
Neither Anticoagulation or Thrombectomy 16 28.57% 66.5%
Only Thrombectomy 17 30.36% 82.4%
Only Anticoagulation 13 23.21% 80.8%
Both Anticoagulation & Thrombectomy 10 17.86% 87.5%

CITATION INFORMATION: Falls M, Said A, Fernandez L, Foley D, Frith K, Hager D, Hoy H, Leverson G, Mezrich J, Prickette T, Wakefield M, D'Alessandro A. Outcomes of Anticoagulation Use for Portal Vein Thrombosis in University of Wisconsin Liver Transplant Patients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Falls M, Said A, Fernandez L, Foley D, Frith K, Hager D, Hoy H, Leverson G, Mezrich J, Prickette T, Wakefield M, D'Alessandro A. Outcomes of Anticoagulation Use for Portal Vein Thrombosis in University of Wisconsin Liver Transplant Patients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-anticoagulation-use-for-portal-vein-thrombosis-in-university-of-wisconsin-liver-transplant-patients/. Accessed May 21, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences